Numinus Wellness (NUMI) investor relations material

Executive summary

• Achieved 81.6% year-over-year revenue growth in Q3 2025, reaching $1.8 million from $992,912 in Q3 2024.

• Transitioned to a leaner operating model, focusing on becoming the backbone for in-clinic delivery of approved psychedelic medicines.

• Up to date with public company filings and preparing to relist after cease trade order is lifted.

Financial highlights

• Consolidated revenues rose to $1.8 million, up 81.6% year-over-year.

• Gross margin improved to 48.2% from a loss of 4.6% in Q3 2024.

• Operating expenditures dropped 59.8% to $1.5 million from $3.8 million year-over-year.

• Ended the quarter with a cash balance of $822,835.

• Loss and comprehensive loss narrowed to $45,975 from $5,766,085 year-over-year.

Outlook and guidance

• Positioned as a bridge between regulatory approval and clinic rollout for psychedelic-assisted therapy.

• Focused on building infrastructure for clinics, including technology for insurance, care integration, and compliance.

• Sector momentum is accelerating with multiple drug candidates nearing regulatory submission.